Mike Krams is a Senior Medical Scientist at Berry Consultants. As an international senior executive, he brings 25 years of experience in pharmaceutical R&D across the full drug development Lifecycle (Discovery, Translational Medicine, Clinical Development, Commercialization), several Therapeutic Areas (Neuroscience, Oncology, Immunology, Infectious Disease) and multiple therapeutic platforms (small molecules, biologics, cell therapy, vaccines). He held global roles in big pharma (Pfizer, Wyeth, JNJ) in early and late clinical development, built and led a 500 people Quantitative Sciences (JNJ), and served as CMO in biotech (Exscientia).

Mike earned his MD at the University of Munich, and trained in Internal Medicine and Neurology. He spent formative years in functional brain imaging at the Institute of Neurology in London. This is where he was first exposed to the power of experimental design to efficiently answer research questions. Ever since he has been passionate for identifying the most appropriate development strategy to make the correct decision at the earliest timepoint in the most efficient manner. He first worked with Don Berry 25 years ago on an innovative response adaptive dose finding study (ASTIN) and has engaged with Berry Consultants ever since. A protagonist for model informed drug development, real time learning and decision making, platform trials and “Integrated Research Platforms” he has established himself as a KOL for adaptive designs and simulation guided clinical trial design, co-chaired PhRMAs working group on adaptive designs, and has established several public private partnerships pushing for innovative designs, including IMI EU PEARL. Mike is interested in exploring the value proposition of Artificial Intelligence and Machine Learning in clinical development and is proud to be part of the world’s leading team in applying Bayesian thinking to clinical development.